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Abstract
Administration of mesenchymal stem cells (MSC) ameliorate experimental autoimmune encephalomyelitis (EAE), a
mouse model of multiple sclerosis (MS), at both clinical and neuropathological levels. The therapeutic properties of
MSC in EAE are mainly mediated by the modulation of pathogenic immune response, but other neurotropic
effects, including decreased demyelination and axonal loss as well as promotion of tissue repair, play also a role.
Properly controlled phase II clinical trials to explore the potential of MSC transplantation as a treatment for MS are
underway. Interferon beta (IFNβ) is an approved treatment for relapsing-remitting and secondary progressive MS.
Here, we explored the possibility that IFNβ might influence the therapeutic potential of MSC, in view of possible
synergistic effects as add-on therapy. IFNβ enhanced the immunomodulatory functions of MSC and induced the
expression of secretory leukocyte protease inhibitor (Slpi) and hepatocyte growth factor (Hgf), two soluble
mediators involved in immune and regenerative functions of MSC. At molecular level, IFNβ induced a rapid and
transient phosphorylation of STAT1 and STAT3, the transcription factors responsible for Slpi and Hgf induction.
Concomitantly, IFNβ dynamically affected the activity of mTOR, a key checkpoint in the control of metabolic
pathways. Indeed, the impairment of mTOR activity observed early upon exposure to IFNβ, was followed by a long-
lasting induction of mTOR signaling, that was associated with an increased glycolytic capacity in MSC. When
induced to switch their energetic metabolism towards glycolysis, MSC showed an improved ability to control T-cell
proliferation. These results suggest that modifications of MSC energetic metabolism induced by IFNβ may
contribute to promote MSC immunomodulatory function and support a role for metabolic pathways in the
therapeutic function of MSC. Altogether, these findings support the idea of a combined treatment for MS, in which
the immunomodulatory and possibly regenerative activity of MSC could be enhanced by the administration
of IFNβ.
Introduction
Mesenchymal Stromal (Stem) Cells (MSC) are a het-
erogeneous subset of stromal progenitors of mesodermal
lineage that have been isolated from almost every tissue,
mainly the bone marrow and adipose tissue. MSC are
defined on the basis of their capability to grow as adherent
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cells on plastic, to display a fibroblast-like morphology, to
form colonies in vitro supporting hematopoiesis, to dif-
ferentiate into cells of the mesodermal lineage and express
stromal while lacking hematopoietic markers1. Several
studies showed that MSC possess immunomodulatory
properties exerted on cells populations of both adaptive
and innate immunity2 and these features, together with
their reported ability to protect neural cells from death
and foster neural repair, account for their proposed
therapeutic effect on multiple sclerosis (MS) and other
neurological diseases3. Intravenous infusion of MSC
improved the clinical course of EAE, inducing immune
tolerance, reducing inflammation decreasing demyelina-
tion and promoting tissue repair4–9. The mechanisms
through which MSC exert their therapeutic function are
heterogenous and probably pleiotropic. It is generally
accepted that MSC immunomodulation is strongly
influenced by cytokines in the inflammatory environment,
particularly by IFN gamma (IFNγ)10,11 and that their
therapeutic effect is mediated by paracrine mechanisms
through the release of soluble factors2. Particularly,
intravenous injection of conditioned medium containing
MSC-derived hepatocyte growth factor (HGF) promoted
remyelination in vitro and tissue repair in vivo12. Auto-
logous MSC have been safely administrated in a limited
number of patients with MS13, and ongoing controlled
clinical studies to explore the potential of MSC trans-
plantation as a treatment for MS have been launched
(Clinical Trial NCT01854957).
Interferon beta (IFNβ) is an approved treatment
for relapsing-remitting14 and secondary progressive
multiple sclerosis (MS). Interferons are a family of
cytokines secreted by various cell types of the innate and
adaptive immune systems as well as by other tissues.
One major pathway in IFNβ signaling involves activa-
tion of Signal Transducer and Activator of Transcrip-
tion (STAT) proteins and formation of complexes that
translocate to the nucleus and bind to specific elements
to regulate gene transcription15. Efficacy of IFNβ for the
treatment of MS is believed to be due to modulation
of immune responses16. Among its functions, in MS
subjects IFNβ modulates dendritic cells17, T and B
lymphocytes18, as well as regulatory NK cells and T
regulatory cells19.
While the potent immunomodulatory effect of IFNβ on
cells of the immune system has been extensively studied,
little is known on the interaction between IFNβ and MSC.
We recently demonstrated that the pro-immunomodulatory
effect of IFNγ on MSC is mediated by the phosphorylation
of STAT1 and STAT3 and by the inhibition of mammalian
target of rapamycin (mTOR) activity11. Thus, we sought to
address the effect of IFNβ on MSC immunomodulatory
functions keeping in mind that, based on the possibility of a
synergic effect, these two treatments could be effectively
associated to treat MS.
Our data showed that IFNβ promoted the ability of MSC
to control T-cell proliferation and enhanced the gene
expression of Hgf and of secretory leukocyte protease
inhibitor (Slpi), an important regulator of innate and
adaptive immunity and a component of tissue regenerative
programs20. At molecular level IFNβ induced a rapid
activation of STAT1 and STAT3 in MSC, concomitant
with an early inhibition followed, at 24 h, by a strong re-
activation of mTOR pathway. The oscillatory switch of
mTOR signaling induced by IFNβ was associated with an
increased glycolytic capacity of MSC, that improved their
ability to control T-cell proliferation.
Materials and methods
MSC culture and treatments
MSC isolated from mouse bone marrow were cultured
in Mesencult medium as described [8]. MSC were treated
with 1500 UI/ml of IFNβ (Rebif ® 44, Merk Serono) for 1
h in serum-free RPMI (Gibco).
Gene silencing
siRNA transfection was carried out using Lipofectamine
2000 in serum free RPMI for 24 h in the presence of specific




As negative control, MSC were transfected with AllStar
siRNA (Qiagen) (CTRL-KD) according to manufacturer’s
instructions. The efficacy of siRNA knock-down was
tested by real time PCR.
Collection of MSC-conditioned medium
Confluent MSC were primed with IFNβ for 1 h in
serum-free RPMI. MSC were washed and cultured for
an additional 24 h in serum-free RPMI with glucose 2 or
4.5 g/L, and the medium was collected (conditioned
medium, CM).
In vitro T-cell proliferation assay
MSC CM equivalent to that of 2 × 104 MSC was assessed
for its effect on proliferation of 2 × 105 anti-CD3/CD28-
activated spleen cells (1:10 ratio) labeled with CFSE (1 µM;
Molecular Probes). Equivalent amount of CM from 3T3
fibroblast culture was used as control. Where the CM of
MSC was collected in RPMI with different concentrations
of glucose (2 or 4.5 g/L), the final glucose concentration in
the T-cell activation medium was 4.5 g/L. Alternatively,
MSC CTRL-KD and SLPI-KD were irradiated (5000 rad)
and added to 2 × 10^5 anti-CD3/CD28-activated spleen
cells (1:10 ratio) labeled with CFSE (1 µM) at the ratio of
Vigo et al. Cell Death and Disease           (2019) 10:85 Page 2 of 8
Official journal of the Cell Death Differentiation Association
1:40. After 72 h, splenocytes were collected and the mean
fluorescence intensity of CD3-positive T cells was evaluated
by flow cytometry. Statistical differences were evaluated
using Student’s T-test.
Real-time PCR
Total RNA was extracted with Trizol (Invitrogen) from
MSC, MSC RAPA, MSC CUC, MSC CTRL-KD and
STAT1-KD 24 h after treatment with IFNβ. Real-time
PCR experiments were conducted as per the manu-
facturer’s instructions (SYBR Green I Master, Roche)






Gene expression values were calculated as 2(−ΔCT) with
hypoxanthine guanine phosphoribosyl transferase (Hprt)
(tcctcctcagaccgctttt/cctggttcatcatcgctaatc) as reference
gene. Statistical differences were evaluated using Student’s
T-test.
Western blot
Total cell lysates and western blot analysis were per-
formed as previously described21. The blots were probed
with antibodies specific for pSTAT1 (Tyr701), pSTAT3
(Tyr705), pS6 (all 1:1000 dilution and from Cell Signaling
Technology, Beverly, MA) and with an actin antibody
(1:1000 from Santa Cruz) to normalize for the amount of
loaded protein.
Pathway inhibition by pharmacological agents
STAT3 inhibition was obtained by exposure of MSC to
cucurbitacin I (CUC) (500 nM; Sigma Aldrich) for 3 h in
serum-free RPMI; mTOR inhibition was obtained
through exposure of MSC to rapamycin (100 nM; Sigma
Aldrich) in serum-free RPMI for 1 h (RAPA). The inhi-
bition of STAT3 and S6 phosphorylation following
treatments was evaluated by Western blot analysis using
phospho-specific antibodies (data not shown).
Immunofluorescence
MSC were fixed in 4% paraformaldehyde, permeabilized
with 0.5% Triton and labeled with antibodies specific for
mouse SLPI (1:100 dilution from Cell Signaling) followed
by a secondary antibody conjugated with AlexaFluor-594.
Nuclei were stained with DAPI. The slides were analyzed
with a Olympus microscopy equipped with 405 and 561
nm filters.
Analysis of MSC metabolism
Real-time measurements of extracellular acidification
rate (ECAR) and oxygen consumption rate (OCR) were
measured using an XFe-96 Extracellular Flux Analyzer
(Seahorse Bioscience). Cells were counted using an
automated Cell counter (Countess from Life Technolo-
gies), seeded in XFe-96 plates (Seahorse Bioscience) at
the density of 2 × 104 cells/well and incubated overnight
at 37 °C in 5% CO2 atmosphere in the presence or absence
of IFNβ (1500UI/ml). ECAR was measured in XF media in
basal condition and in response to 10 mM glucose, 4 μM
oligomycin and 100 mM of 2-Deoxy-D-glucose (2-DG).
Basal glycolysis was calculated after glucose injection
(subtracting the ECAR rate inhibited by 2DG). Maximal
glycolysis was measured after oligomycin injection and
glycolytic capacity as the difference of oligomycin-
induced ECAR and 2-DG-induced ECAR. OCR was
measured in XF media (non-buffered DMEM medium,
containing 10 mM glucose, 2 mM L-glutamine, and 1mM
sodium pyruvate), under basal conditions and in response
to 5 μM oligomycin, 1.5 μM of carbonylcyanide-4-(tri-
fluoromethoxy)-phenylhydrazone (FCCP) and 1 μM of
antimycin A and rotenone (all chemicals from Sigma
Aldrich). Basal OCR was calculated as the difference
between baseline measurements and antimycin A/rote-
none-induced OCR; maximal OCR was measured as the
difference between FCCP-induced OCR and antimycin
A/rotenone-induced OCR. Finally, the ATP-linked para-
meter was calculated as the difference between baseline
measurements, without injection, and oligomycin-
induced OCR. Experiments with the Seahorse system
were done with the following assay conditions: 3 min
mixture; 3 min wait; and 3min measurement. Then,
metabolic parameters were calculated. Data are expressed
as mean and S.E.M. from four independent experiments.
Statistical differences were evaluated using the Wilcoxon
matched-pairs test.
Results
IFNβ promoted MSC immunomodulation inducing the
expression of secreted mediators
To verify the possibility that IFNβ may affect the
expression of immunomodulatory factors secreted by
MSC we analyzed, 24 h upon priming with IFNβ, the
mRNA levels of Cd274, Ccl2, and Hgf, which are known to
act in a paracrine way on immune cells. We also assessed
the gene expression of Il18bp and Slpi, that we recently
identified as induced in MSC upon interaction with
activated T cells11. As shown Fig. 1a, IFNβ induced a
significant increase of mRNA level of all the genes ana-
lyzed. We then focused on Slpi, whose role in MSC
immunomodulation has never been reported. We first
confirmed that MSC exposed to IFNβ increased Slpi
expression at protein level (Fig. 1b). To get some insight
into the role of Slpi on MSC immunoregulatory function,
we reduced its expression in MSC through gene silencing
(SLPI-KD) and used these Slpi-silenced cells to inhibit
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T-cell proliferation (Fig. 1c). As shown in Fig. 1d, MSC
SLPI-KD showed a reduced ability to inhibit T-cell pro-
liferation in vitro as compared to MSC transfected with
control siRNA (CTRL-KD).
Then we sought to verify if IFNβ was able to affect the
ability of MSC to control T-cell proliferation priming
MSC with IFNβ and testing the effect of the derived
conditioned medium (CM) on activated T cells. As shown
in Fig. 1e, IFNβ significantly enhanced the constitutive
immunomodulatory effect of MSC CM.
These results demonstrated that IFNβ induced in MSC
the expression of soluble immunomodulatory factors and
concomitantly improved their ability to inhibit T-cell
proliferation in vitro.
IFNβ induced dynamic changes in STAT1, STAT3, and S6
phosphorylation
As activation of STAT1 and STAT3, and inhibition of
mTOR pathway positively affects MSC immunomodula-
tory function upon administration of interferon gamma
(IFNγ)11, we analyzed the activation state of these
pathways following exposure to IFNβ. Analysis of phos-
phorylated pathway components revealed that exposure
to IFNβ for 1 h dramatically increased the levels of
phosphorylated STAT1 (pSTAT1) and STAT3 (pSTAT3)
and concomitantly reduced the amount of phosphorylated
S6 (pS6), used as read-out of mTOR activity (Fig. 2b).
Upon a prolonged exposure (24 h), pSTAT1 and pSTAT3
decreased as compared to 1 h, indicating that IFNβ
induced a a transient phosphorylation of STAT1 and
STAT3. Concomitantly, the levels of pS6 strongly
increased as compared to that observed upon exposure to
IFNβ for 1 h, revealing that IFNβ induced an oscillatory
modification of mTOR pathway activity (Fig. 2a, b).
IFNβ-dependent expression of Slpi and Hgf was mediated
by STAT1 and STAT3
Engagment of STAT1 and STAT3 induces the expres-
sion of immunomodulatory genes in MSC, that is further
enhanced by inhibition of mTOR signaling11. To assess
Fig. 1 IFNβ induced the expression of soluble mediators and promoted MSC immunomodulatory function. a Real-time PCR analysis of
immunoregulatory genes in MSC exposed or not to IFNβ. Data are mean ± SD (n= 3); b Immunofluorescence analysis of Slpi expression in MSC. Red,
SLPI; blue, DAPI; c Real-time PCR analysis of Slpi expression was evaluated in MSC following transfection with specific siRNA (MSC SLPI-KD) and
compared to that of control MSC (MSC CTRL-KD). Data are mean ± SD (n= 3); d In vitro T-cell proliferation assay in the presence of MSC CTRL-KD and
MSC SLPI-KD. MSC were added at the ratio 1:40 with activated splenocytes. Data are presented as mean ± SD (n= 3); e In vitro T-cell proliferation in
the presence of MSC conditioned medium (MSC CM) collected after priming with IFNβ (IFN CM). The CM of 3T3 fibroblast culture was used as
control. Data are mean ± SD (n= 3)
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the role of these pathways in the induction of Slpi and Hgf
by IFNβ, we inhibited STAT1 through gene silencing,
STAT3 using the chemical inhibitor Cucurbitacin I
(CUC) and mTOR with its inhibitor rapamycin (RAPA)
before the exposure to IFNβ and we analyzed Slpi and Hgf
expression by real-time PCR. We observed that the
induction of Slpi expression by IFNβ was significantly
impaired by STAT1 and STAT3 inhibition, while the
blockade of mTOR pathway did not exert any affect on
their expression (Fig. 2c). Similarly, we observed that
impairment of STAT1 and STAT3 signaling, but not that
of mTOR, reduced the induction of Hgf upon exposure to
IFNβ (Fig. 2d).
Exposure to IFNβ modified MSC energetic metabolism
As IFNβ affected the activity of mTOR pathway, a
master regulator of intracellular metabolism, we assessed
whether exposure to IFNβ could impact on the bioener-
getic profile of MSC, by measuring extracellular acid-
ification rate (ECAR) as an indicator of glycolysis, and
oxygen consumption rate (OCR) indicator of mitochon-
drial respiration. We observed that IFNβ did not modify
basal glycolysis in MSC (Fig. 3a, b). However, maximal
glycolysis (induced by oligomycin injection) and glycolytic
capacity were significantly increased by IFNβ treatment,
as compared to untreated MSC (Fig. 3a, b). Then we
investigated mitochondrial respiration in terms of OCR.
IFNβ did not affect maximal OCR and OCR coupled to
ATP generation, but slightly enhanced the respiratory
capacity of MSC in basal conditions (Fig. 3c, d), indicating
that IFNβ preferentially increased the glycolytic capacity
of MSC.
Glycolisis engagement improved MSC immunomodulatory
function
To link MSC glucose metabolism with their immuno-
modulatory function, we assessed whether or not
improvement of MSC glycolitic rate may impact on their
capacity to inhibit T-cell proliferation. We boosted gly-
colitic flux by growing MSC in high glucose containing
medium (4.5 g/L), and we assessed the immunomodula-
tory properties of the resulting CM in T-cell proliferation
assay. We obtained a significant improvement in the
constitutive ability of MSC CM to inhibit T-cell pro-
liferation by collecting MSC CM in high glucose-
containing medium as compared to MSC CM prepared
in normal medium (2 g/L) (Fig. 4).
These results clearly demonstrated that promoting
glucose metabolism improved the immunomodulatory
function of MSC, thus suggesting a new possible
mechanism through which IFNβ enhances MSC
immunomodulation.
Fig. 2 IFNβ induced dynamic changes in STAT1, STAT3, and S6 phosphorylation. aWestern blot analysis conducted after 1 or 24 h of incubation
with IFNβ. Actin served as loading control; b relative densitometric quantitation of the shown gel, after normalization on actin; c, d Real-time PCR
analysis of Slpi and Hgf expression in MSC exposed to IFNβ upon pathway inhibition. Data are presented as mean ± SD (n= 3)
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Discussion
While the potent immunomodulatory effect of IFNβ on
cell types of the immune system has been extensively
studied22, little is known on the interaction between IFNβ
and MSC. IFNβ was shown to influence the expression of
chemokines and their receptors in human MSC23, but the
effects of IFNβ on MSC immunomodulatory function are
largely unknown. Our data demonstrated that IFNβ sig-
nificantly increased the expression of molecules, secreted
by MSC, with reported immunomodulatory activities.
Among those, we observed that Slpi, a molecule never
related to MSC biology, potentiated the ability of MSC to
control T-cell proliferation in vitro.
Slpi is a polypeptide secreted by epithelial cells to pro-
tect tissue from damage by leucocyte proteolytic enzymes.
Nevertheless, the regulatory function of Slpi on adaptive
immunity is independent to its anti-protease activity. Slpi
has been demonstrated to affect the monocyte pattern
secretion by preventing the interaction of p65 with the
NF-kB binding sites24, to inhibit effector T-cell pro-
liferation25 and to promote the generation of regulatory
T cells26. Slpi is upregulated in macrophages, activated
microglia, neuronal cells and astrocytes during EAE
attack27. Interestingly, Slpi was shown to increase pro-
liferation of adult neural stem cells promoting oligoden-
droglial differentiation, as incubation of adult neural stem
cells with recombinant Slpi resulted in an increase of cell
Fig. 3 Exposure to IFNβ modified MSC energetic metabolism. a Kinetic profile of ECAR in MSC treated or not with IFNβ for 12 h. The data are
shown as mean ± S.E.M. of four independent experiments. ECAR was measured in real time, under basal conditions and in response to glucose,
oligomycin and 2-DG; b parameters of glycolysis in MSC were calculated as detailed in Materials and methods. Data are expressed as mean ± S.E.M. of
three measurements, from four independent experiments; c kinetic profile of OCR in MSC treated or not with IFNβ for 12 h. The data are shown as
mean ± S.E.M. of four independent experiments. OCR was measured in real time, under basal conditions and in response to oligomycin, FCCP and
Antimycin A+ Rotenone. d Parameters of mitochondrial respiration in MSC were calculated as detailed in material and methods. Data are expressed
as mean ± S.E.M. of three measurements, from four independent experiments
Fig. 4 Promotion of MSC glycolisis improved their ability to
inhibit T-cell proliferation in vitro. In vitro T-cell proliferation assay in
the presence of conditioned medium of MSC (MSC CM) collected in
serum-free RPMI at different concentration of glucose (2 g/L or 4, 5 g/L).
The final glucose concentration in the T-cell activation medium was 4.5
g/L. Data are mean ± SD (n= 3)
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proliferation and of differentiation towards oligoden-
drocytes27. Whether Slpi secreted by MSC may play a role
also in tissue repair promoted by MSC requires further
investigation. Interestingly IFNβ significantly enhanced
also the expression of Hgf a pleiotropic cytokine with
neuroprotective which has been demonstrated to enhance
axonal outgrowth and oligodendroglial maturation12.
At molecular level, IFNβ induced a transient phos-
phorylation of STAT1 and STAT3, determining the
induction of Slpi and Hgf expression, that was indeed
impaired by both STAT1 and STAT3 inhibition. Con-
comitantly, IFNβ induced a dynamic modification of
mTOR activity, that was early reduced and then increased.
In line with the role of mTOR in the control of glucose
metabolism, a prolonged exposure to IFNβ increased
MSC glycolytic capacity, thus improving their ability to
engage glycolysis to convert glucose to pyruvate or lactate.
Energy metabolism and functional activation are fully
integrated in immune cells to determine their ability to
divide, differentiate, and carry out effector functions28.
Here we found that inhibition of T-cell proliferation by
MSC was strongly enhanced by boosting MSC glycolisis.
As ECAR, monitored as readout of MSC glycolitic activity,
was mainly due to production of lactate, our data suggest
the possible involvement of lactic acid in MSC immuno-
modulatory function. Lactic acid had been shown to
suppress the proliferation and cytokine production of
human cytotoxic T lymphocytes29 and to inhibit TNF
secretion and glycolysis of human monocytes30.
Our data support that IFNβ can enhance MSC ther-
apeutic function through two different molecular
mechanisms: the early induction of STAT1-3-dependent
immunomodulatory genes, and the long-lasting mTOR-
associated promotion of glucose metabolism. Particularly,
based on the finding that IFNβ induced the expression of
cytokines with both immunomodulatory and neuropro-
tective features such as Hgf and Slpi, we speculate that
MSC as add-on therapy to IFNβ treatment could promote
tissue repair beyond modulation of inflammatory reac-
tions. In line with these results, administration of IFNβ-
secreting engineered MSC has been demonstrated to be
more effective than wild-type MSC in the attenuation of
EAE31,32, further supporting the rationale for combined
protocols to treat MS. Moreover, the finding that MSC
immunomodulatory function is improved by glucose
metabolism revealed a new possible mechanism under-
lying MSC therapeutic effect.
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